The global diabetes devices market is entering a phase of strong growth and transformation. Valued at US$ 32.4 billion in 2024, it is expected to reach US$ 70.6 billion by 2035, expanding at a CAGR of 7.4% from 2025 to 2035. This impressive expansion reflects rising diabetes prevalence, technological progress, and growing global awareness of chronic disease management. Devices such as continuous glucose monitoring (CGM) systems, insulin pumps, and connected digital platforms are reshaping how patients monitor and manage their condition, creating a more data-driven and personalized healthcare environment.
Growth Drivers
The foremost driver of the diabetes devices market is the rising global burden of diabetes. According to international health organizations, the number of adults with diabetes continues to climb due to aging populations, sedentary lifestyles, and poor dietary habits. This growing patient base has increased the demand for convenient, accurate, and less invasive monitoring and insulin delivery solutions.
Technological innovation is another major catalyst. Continuous glucose monitoring systems now provide real-time feedback and integrate seamlessly with smartphones and wearable technology. The latest insulin pumps are increasingly automated, forming part of closed-loop systems that mimic pancreatic function by adjusting insulin doses based on glucose readings. These “artificial pancreas” systems represent a leap forward in improving patient safety and quality of life.
Supportive government policies and reimbursement frameworks are also contributing to market growth. In developed regions, favorable insurance coverage for advanced diabetes devices has boosted adoption rates. Meanwhile, emerging economies are making significant investments in public health infrastructure, raising awareness, and promoting early diagnosis—all of which are expanding access to modern diabetes care solutions.
Report Scope and Segmentation
The diabetes devices market is segmented by product type, end user, and region.
By product type, the market is divided into glucose monitoring devices and insulin delivery devices. Glucose monitoring devices include SMBG meters, CGM systems, test strips, and lancets, with CGM devices expected to dominate future demand thanks to their continuous, real-time functionality. Insulin delivery devices—such as pumps, pens, and injectors—are also seeing rapid growth, driven by the increasing preference for compact, wearable, and tubeless pump systems that enhance user comfort and convenience.
By end user, hospitals, clinics, homecare, and diagnostic centers represent the key segments. The homecare segment is growing fastest as patients seek greater independence in managing their condition. The integration of remote monitoring and mobile health applications supports this shift, enabling healthcare providers to track patient data and adjust treatment plans in real time.
Regional Analysis
North America leads the global market due to its high prevalence of diabetes, advanced healthcare systems, and early adoption of innovative devices. The U.S. market, in particular, benefits from strong reimbursement support and the presence of key industry players such as Medtronic, Abbott, and Insulet Corporation. Europe follows closely, supported by well-established healthcare infrastructure and growing partnerships between medical device companies and healthcare institutions. The region also benefits from widespread government initiatives encouraging preventive health and chronic disease management.
Asia-Pacific is the fastest-growing regional market. Rapid urbanization, changing diets, and economic growth have led to a surge in diabetes cases in China, India, and Southeast Asia. Growing healthcare expenditure and expanding distribution networks are making advanced diabetes devices more accessible. Meanwhile, Latin America and the Middle East & Africa are emerging markets with significant long-term potential, as awareness campaigns and local manufacturing efforts help improve affordability and reach.
Competitive Analysis
The diabetes devices industry is highly competitive, featuring both global leaders and innovative regional players. Prominent companies include Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc., SOOIL Developments Co., Ltd., F. Hoffmann-La Roche AG, Ypsomed, Terumo Corporation, MicroTech Medical, Inc., Jiangsu Delfu Co., Ltd., Medtrum Technologies Inc., Novo Nordisk A/S, Sanofi, and Abbott Laboratories. These companies are investing heavily in research and development to enhance device performance, connectivity, and user experience. Partnerships and acquisitions are frequent strategies aimed at expanding portfolios and integrating digital health technologies.
The industry’s competitive edge increasingly lies in data integration—linking glucose monitoring and insulin delivery with mobile platforms that offer analytics, alerts, and physician connectivity. As these technologies evolve, the focus will continue to shift toward seamless, personalized, and preventive diabetes management.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
